Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Key Highlights
- ➤Aprea (APRE) CEO Oren Gilad will present at Guggenheim’s healthcare conference November 9
- ➤Aprea will hold investor meetings during the November 9-11 healthcare conference
- ➤APR-1051 oral WEE1 inhibitor and ATRN-119 ATR inhibitor remain in clinical development
- ➤Aprea targets ovarian, colorectal, prostate, and breast cancers with precision oncology therapies
Expert Statements
Oren Gilad, President and Chief Executive Officer of Aprea Therapeutics
“will participate in a fireside chat and meet with investors at Guggenheim’s 3rd Annual Healthcare Innovation Conference”
DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and meet with investors at Guggenheim’s 3rd Annual Healthcare Innovation Conference, to be held November 9-11, 2026 in Boston, MA.
Those interested in arranging a one-on-one meeting with Dr. Gilad should contact their Guggenheim representative.
Get started
Create a free account to read the full story.